Related Experiment Video
Updated: Mar 1, 2026
PET and MRI Guided Irradiation of a Glioblastoma Rat Model Using a Micro-irradiator
Published on: December 28, 2017
Radiation-agent combinations for glioblastoma: challenges in drug development and future considerations
Charles A Kunos1, Evanthia Galanis2, Jeffrey Buchsbaum3
1Investigational Drug Branch, Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, MD, USA.
Abstract:
Glioblastoma is an aggressive disease characterized by moderate initial response rates to first-line radiation-chemotherapy intervention followed by low poor response rates to second-line intervention. This article discusses novel strategic platforms for the development of radiation-investigational agent combination clinical trials for primary and recurrent glioblastoma in a NCI-NCTN settings with simultaneous analysis of challenges in the drug development process.
Insights
Glioblastoma treatment shows initial promise but faces challenges in later stages. Novel clinical trial strategies are needed for better radiation-chemotherapy combinations in glioblastoma therapy.
Area of Science:
- Neuro-oncology
- Clinical trial design
- Radiation oncology
Background:
- Glioblastoma exhibits limited response to standard treatments.
- Recurrent glioblastoma presents significant therapeutic challenges.
- Current treatment paradigms require innovative approaches.
Purpose of the Study:
- To explore novel strategic platforms for glioblastoma clinical trials.
- To facilitate the development of radiation-investigational agent combinations.
- To address challenges in drug development for glioblastoma.
Main Methods:
- Discussion of strategic platforms for clinical trial development.
- Analysis of combination therapies involving radiation and investigational agents.
- Examination of NCI-NCTN trial settings.
Main Results:
- Identified challenges in the glioblastoma drug development process.
- Proposed novel strategic platforms for clinical trial design.
- Highlighted the need for improved combination interventions.
Conclusions:
- Novel strategies are crucial for advancing glioblastoma treatment.
- Addressing drug development challenges can improve therapeutic outcomes.
- Combination trials offer a promising avenue for primary and recurrent glioblastoma.
